Overlap phenotypes of the left ventricular noncompaction and hypertrophic cardiomyopathy with complex arrhythmias and heart failure induced by the novel truncated DSC2 mutation

Abstract

Background

The left ventricular noncompaction cardiomyopathy (LVNC) is a rare subtype of cardiomyopathy associated with a high risk of heart failure (HF), thromboembolism, arrhythmia, and sudden cardiac death.

Methods

The proband with overlap phenotypes of LVNC and hypertrophic cardiomyopathy (HCM) complicates atrial fibrillation (AF), ventricular tachycardia (VT), and HF due to the diffuse myocardial lesion, which were diagnosed by electrocardiogram, echocardiogram and cardiac magnetic resonance imaging. Peripheral blood was collected from the proband and his relatives. DNA was extracted from the peripheral blood of proband for high-throughput target capture sequencing. The Sanger sequence verified the variants. The protein was extracted from the skin of the proband and healthy volunteer. The expression difference of desmocollin2 was detected by Western blot.

Results

The novel heterozygous truncated mutation (p.K47Rfs*2) of the DSC2 gene encoding an important component of desmosomes was detected by targeted capture sequencing. The western blots showed that the expressing level of functional desmocollin2 protein (~ 94kd) was lower in the proband than that in the healthy volunteer, indicating that DSC2 p.K47Rfs*2 obviously reduced the functional desmocollin2 protein expression in the proband.

Conclusion

The heterozygous DSC2 p.K47Rfs*2 remarkably and abnormally reduced the functional desmocollin2 expression, which may potentially induce the overlap phenotypes of LVNC and HCM, complicating AF, VT, and HF.

Introduction

The left ventricular noncompaction cardiomyopathy (LVNC) is a rare subtype of cardiomyopathy (CM) and is characterized by predominant left ventricular trabeculations with deep intertrabecular recesses and thinning of the compact epicardium [1]. LVNC can coexist with dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic cardiomyopathy (ACM) [2–4]. LVNC is an inherited cardiac disease, classified as primary genetic CM, and associated with high risks of syncope, chest pain, heart failure (HF), malignant arrhythmia, sudden cardiac death (SCD), and thromboembolism [5]. A recent systematic review illustrated that the risks of thromboembolism and ventricular arrhythmias in LVNC are similar to DCM. Additionally, LVNC has a higher incidence of HF hospitalization than DCM. The low left ventricular ejection fraction (LVEF) induced by LVNC is associated with a poor prognosis [6]. A previous genetic study indicated that the mutations of genes encoding sarcomeric proteins account for up to 30% of LVNC [7]. Other common mutations of genes encoding cytoskeletal, Z-line, and mitochondrial proteins include myosin heavy chain (MYH7), protein-binding protein C myosin (MYBPC3), tropomyosin alfa (TPM1), myocardial actin (ACTC1), troponin T (TNNT2), and cardiac troponin I. The less common mutations of genes inducing LVNC include Z-band protein mutations, such as Cypher/ZASP cytoskeleton protein, alpha-distrobrevin (DTNA), calcium transport proteins, calsequestrin, phospholamban, membrane proteins (A/C lamina), para-zinc-finger transcription factor [8], and mitochondrial enzymes. Our study identifies a proband with rare overlap phenotypes of LVNC and HCM from a Chinese Han family and explores the potential pathogenesis via genetic screening and molecular experiments.

Material and methods

Patients and clinical variables

All participants signed informed consent. All procedures performed in the study involving human participants were in accordance with the Declaration of Helsinki and ethical standards and were approved by the Medicine Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University (No. 2020K216-1).

In accordance with previous studies [1, 9], LVNC was diagnosed by cardiologists based on clinical presentation and interpretation of echocardiogram and cardiac magnetic resonance imaging (CMRI) results by using the Jenni and Petersen criteria, respectively [10, 11]. The LVNC diagnosis was based on the presence of an end-systolic ratio of the noncompacted layer to compacted layer above 2 (NC/C ≥ 2.0) on echocardiography [10] and/or an end-diastolic ratio between the noncompacted and compacted layer greater than 2.3/2.0 (NC/C ≥ 2.3/2.0) in the long/short-axis view of CMRI with specificity and negative predictive values of 99% [11]. The left ventricular systolic dysfunction was defined as systolic LVEF < 50% by echocardiogram [1]. The clinical assessment also included physical examination and 12-lead and Holter electrocardiograms (ECGs). The N-terminal of B-type natriuretic peptide precursor (NT-proBNP) assays was performed at a central independent laboratory using a commercially available kit (Roche Diagnostics, Mannheim, Germany). We obtained the skin and subcutaneous tissue of the upper left limb of the patient (II: 1) and healthy volunteer through small surgery and carried out molecular biological detection. The healthy volunteer was a 37-year-old male without cardiac diseases verified by ECG and echocardiogram.

CMRI

Imaging was acquired using the 1.5 T MR imaging system (MAGNETOM Aera, Siemens Healthcare, Germany) by using a 6-channel phased-array coil. After scout and reference scans, functional and geometric assessments were achieved using ECG-gated, cine steady-state-free precession images in standard long- (2-, 3-, and 4-chamber views) and short-axis orientations with full ventricle coverage from basis to apex. Left and right ventricular outflow tract cine sequences were also obtained. Cine images with a temporal resolution of approximately 40 ms were obtained. Additional pulse sequences, including T1WI and T2WI of blood-suppressed double inversion recovery fast spin-echo, were acquired in a standard location before contrast administration. Then, the dynamic enhancement was performed during the administration of 0.2 mmol/kg contrast agent (Gadovist, Bayer Healthcare, Berlin, Germany) with 50 frames. Late gadolinium-enhanced imaging was performed with 20 min delay and phase-sensitive inversion recovery sequence to detect myocardial scarring or fibrosis. CMRI analyses were performed using SigoVia (Siemens). The functional and geometric left ventricular indices, including left and right ventricular end-diastolic volumes, LVEF and right ventricular ejection fraction, indexed left ventricular compacted mass with papillary muscles, indexed left ventricular compacted and noncompacted mass, indexed left ventricular noncompacted mass, and their ratio was determined. In addition, the end-diastolic extent of compacted and noncompacted myocardium and their ratio were measured in one long axis geometry.

Collection of human specimens and target capture sequencing

Skin biopsies were collected from the upper left arm of the proband and healthy volunteer. Protein was extracted from tissues. Peripheral blood was collected from the proband and his relatives. DNA was extracted (using D3537-02#MagPure Buffy Coat DNA Midi KF Kit, Magen, Beijing, China) from the peripheral blood of proband for high-throughput target capture sequencing using Gene fragment capture chip (MGI BGI EXOME V4, Shenzhen, China) and MGIseq-2000 sequencer (MGI, Shenzhen, China). The panel of common risk genes associated with CMs and arrhythmias (Table 1) was detected in the proband (II: 1). SNPs and Indels were annotated using a pipeline, in which all insertion and deletion variants occurring at coding regions were considered damaging. Nonsynonymous SNPs were predicted using the SIFT (http://sift.jcvi.org/www/), PolyPhen-2 (Polymorphism Phenotyping v2, http://genetics.bwh.harvard.edu/pph2/), and MetaSVM [12]. Variants were classified as “pathogenic (P)”, “likely pathogenic (LP)”, “uncertain significance (US or VUS)”, “likely benign (LB)”, or “benign (B)” by using the InterVar tool [13] following the 2015 ACMG/ACP guidelines [14]. Variants in predisposing genes associated with hereditary arrhythmias and CMs were screened, and the filtering criteria were as follows: (1) same variants in the WES data; (2) missense, nonsense, insertion, and deletion variants; and (3) SNPs with minor allele frequency < 0.01 according to the SNP database of National Center. Other familial members were validated using the Sanger sequencing for potentially pathogenic genes. Details are shown in our previous research [15].

Table 1.

Susceptible genes of inherited cardiomyopathy and arrhythmia detected in the proband II: 1

A2M, AARS2, ABCA1, ABCC6, ABCC9, ABCD4, ABCG5, ABCG8, ACE, ACTA2, ACTC1, ACTN2, ACVRL1, AGT, AGTR1, AKAP9, AKAP10, ALPK3, AMPD1, ANK2, ANK3, APBB2, APOA2, APOB, APP, ARFGEF2, ARSA, ASPA, BAG3, BCS1L, BLM, BLMH, BMP1, BMPR2, BRAF, CACNA1C, CACNA2D1, CACNB2, CALR3, CASQ2, CAV3, CBL, CBS, CCM2, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COX10, COX15, CRELD1, CRTAP, CRYAB, CSRP3, CST3, CTNNA3, DES, DPP6, DSC2, DSG2, DSP, DTNA, ELN, EMD, ENG, ENPP1, ERCC6, ERCC8, ESR1, EYA4, F2, F5, F7, F12, F13A1, FBN1, FKBP10, FKBP12, FKTN, FLNC, FOXRED1, GALC, GATA4, GATA6, GATAD1, GCLC, GDF1, GFAP, GHR, GJA1, GJA5, GLA, GNAI2, GPD1L, GSN, GUCY1A3, HADHB, HBB, HCFC1, HCN4, HEY2, HFE, HTRA1, IFITM5, ITGB3, ITM2B, JAG1, JAK2, JARID2, JPH2, JUP, KCNA5, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNMB1, KCNQ1, KRAS,TAZ, KRIT1, LAMA4, LAMP2, LDB3, LDLR, LDLRAP1, LMBRD1, LMNA, LMX1B, LRP6, LTA, MAPT, MED13L, MEF2A, MIB1, MIB2, MIPEP, MLC1, MLYCD, MMACHC, MMADHC, MPO, MTHFR, MTR, MTRR, MYBPC3, MYH3, MYH6, MYH7, MYH11, MYL2, MYL3, MYLK2, MYOT, MYOZ2, MYPN, NEXN, NDUFA2, NDUFA9, NDUFA10, NDUFA12, NDUFAF2, NDUFAF6, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NEBL, NKX2.5, NKX2.6, NNT, NONO, NOS3, NOTCH1, NPPA, NRAS, NRG1, NSD1, OBSCN, PCSK9, PDCD10, PDE4D, PDLIM3, PKD1, PKD2, PKP2, PLAU, PLEKHM2, PLN, PLP1, PlXND1, PMP22, PPIB, PRDM16, PRKAG2, PRKAR1A, PSEN1, PSEN2, PTPN11, RAF1, RASA1, RBM20, REN, RNF213, RYR2, SORL1, RPS6KA3, SCN1B, SCN3B, SCN4B, SCN5A, SDHA, SDHAF1, SDHD, SERPINE1, SERPINF1, SERPINH1, SGCD, SH2B1, SHOC2, SLC6A4, SLC25A4, SLC39A8, SMAD3, SMAD4, SMC1A, SNTA1, SOS1, SP7, SPARC, STRA6, SURF1, TBX1, TBX5, TBX20, TCAP, TGFB2, TGFB3, TGFBR1, TGFBR2, TLL1, TMEM38B, TMEM43, TMEM70, TNNC1, TNNI2, TNNI3, TNNT2, TNNT3, TPM1, TPM2, TREX1, TRPM4, TSC2, TSPYL1, TTN, TTR, VCL, VKORC1, WNT1, YWHAE, ZFPM2

ACMG classification

According to ACMG standards and guidelines, all variants have been reclassified for interpreting sequence variants as P, LP, VUS, LB, or B [14]. The PM2 item in the ACMG classification is considered fulfilled if minor allele frequency (MAF) in relevant population databases is ≤ 0.1% [16]. The vast majority of reported pathogenic variants in arrhythmia and CM are extremely rare (MAF < 0.01%) [17]. The classification “high degree of pathogenicity” (item PVS1) should only be used for rare variants in genes where the loss of function is a well-established disease mechanism [18–20]. In the case of VUS, a rare variant classified as ambiguous does not provide molecular confirmation of a diagnosis. Still, it cannot be discarded as indicating a low risk of malignant arrhythmias for any patient, at least until additional data clarify its clinical role [21]. The VUS changed to LB due to a substantial increase of MAF seen with ongoing analysis of the global population, which notes the key role of global frequencies and its correlation with the prevalence of inherited arrhythmia and CM in the population [19]. Previous studies showed VUS rarely changed to P or LP variants [22].

Sanger sequencing

The variant of DSC2 p.I520T was screened again using Sanger sequencing (CX0020, TSINGKE Biological technology, Guangzhou, China) in the other members of the family. The mutation of DSC2 p.K47Rfs*2 was screened again using the TA cloning technique in the other familial members. The purified PCR product was directly linked with pClone007 Versatile Simple Vector (TSINGKE Biological technology, Guangzhou, China) by TA cloning technique and transformed into Escherichia coli (DH5α). The extracted plasmids were sequenced with ABI 3730XL (Applied Biosystem, USA). The primer of TA cloning sequencing was as follows: M13F-47:5′-CGCCAGGGTTTTCCCAGTCACGAC-3′. The primer designed with Primer Premier 5.0 was used and showed as follows: forward primer, 5′-AAGGCTATTAGAAAGCAGAC-3′; reverse primer 5′-ATATGACCCAGAAACAAGAA-3′.

Western blot

Tissues were homogenized on ice in the lysis buffer. After centrifugation and protein quantification, proteins were loaded onto SDS–PAGE gels and transferred onto nitrocellulose membranes. Membranes were incubated in 5% nonfat dry milk in TBST for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies. Rabbit anti-DSC2 and mouse anti-β-actin antibody were purchased from Abcam Inc (Cambridge, MA). Antibodies were detected using 1:10,000 horseradish peroxidase-conjugated, donkey anti-rabbit, and donkey anti-mouse IgG (Jackson ImmunoResearch, USA). The Western blot luminol reagent was used to visualize bands corresponding to each antibody.

Results

Clinical presentation

The familial pedigree is shown in Fig. 1A. A male patient (proband, II: 1) aged 54 years was admitted to our hospital because of recurrent chest dullness and chest pain for three years and exacerbation for half a month. He suffered from poststernal chest distress and palm-sized chest pain, which were sometimes accompanied by palpitation. Symptoms usually occur during exhaustion and could be relieved after taking a break. The Holter of II: 1 (oral bisoprolol, 5 mg, once a day) showed persistent atrial fibrillation (AF) with a long RR interval of 3.95 seconds, low voltage in limb lead, and T wave inversion in leads of V₄–V₆ (Fig. 2A). The frequently paired premature ventricular extrasystoles (PVCs) originated from the left ventricular lateral wall (Fig. 2B), left ventricular apex (Fig. 2C), and left ventricular inflow tract (Fig. 2D). The episodes of ventricular tachycardia (VT) originated from the middle posterior septum (Fig. 2E) and lateral wall (Fig. 2F) of the left ventricle (LV). Coronary heart disease was excluded by coronary angiography. The level of NT-proBNP was 13,800.00 pg/ml (normal range: 0–125 pg/ml) during hospitalization and increased continuously during the follow-up.

Fig. 1.

The familial pedigree, Sanger sequencing and the change of desmocollin2 protein. A: The pedigree of the family. II: 1 (the proband) presented with LVNC and HCM, complicating AF, VT and HF. SCD: sudden cardiac death. B: Sanger sequencing of DSC2 variants in the family members. Sanger sequencing revealed that II: 1 carried two variants of DSC2 p.K47Rfs*2 and p.I520T, which were not detected in II: 2. II: 3 only carried with DSC2 p.I520T variant. C: the protein of desmocollin2 consists of several domains, including signaling peptide (S), proprotein (P), four extracellular cadherin domains (EC), extracellular anchor domain (EA), the transmembrane region (TM), the intracellular anchor (IA), as well as the intracellular cytoplasmic domain (ICS). X: the lost domains of desmocollin2 protein induced by DSC2 p.K47Rfs*2 mutation. D: conservative analysis of DSC2 p.I520

Fig. 2.

The electrocardiograms of familial members

Echocardiography (Fig. 3) demonstrated the enlarged LV, thickened interventricular septum, thinning posterior wall of LV, and slightly enlarged right atrium. In addition, LV, especially the posterior and inferior walls, was hypokinetic and had an LVEF of 34%. The ratio of the non-compacted layer to compacted layer in LV was more than two folds at the end-systolic period of LV. The typical forward blood flowed from the ventricular cavity into the deep spaces between the prominent trabeculations during diastole. CMRI (Fig. 4) demonstrated that the ratio of the non-compacted layer to compacted layer at the end-diastolic period of LV was from 2.25 to 2.67. Deep recesses with slow blood flow could be seen among the trabeculae carneae, which communicated with the LV lumen, and this finding was consistent with the LVNC diagnosis. The basal segment, intermediate segment, anterior wall, and anterolateral wall of LV were thickened with increased, rough, and disorderly arranged trabeculae carneae in the subendocardial layer. The interventricular septum was thickened with a diameter of 18 mm. These changes suggested the combined phenotypes of LVNC and HCM. No apparent abnormal lipid signal deposition was observed in LV and right ventricle. II: 1 was administered with dabigatran (110 mg, orally, twice a day), fluvastatin (80 mg, orally, once each night), sakubatrovalsartan (50 mg, orally, twice a day), and trimetazidine (20 mg, orally, three times a day) for CMs, AF, VT, and HF therapy and metformin (50 mg, orally, three times a day) and carbamazin (100 mg, orally, once a day) for diabetes mellitus therapy since 10 years ago. II: 1 had the indication for implantable intracardiac defibrillator but refused implantation.

Fig. 3.

Echocardiographic characteristics of the proband II: 1. A To quantify the extent of noncompaction at the site of maximal wall thickness. The end-systolic ratio of noncompacted to compacted thickness was determined. The two layers were best visualized at end-systole as shown in this long-axis view (N, non-compacted layer; C, compacted layer). B, C Color Doppler study showed typical forward blood flow from the ventricular cavity into the deep spaces between the prominent trabeculations during diastole (in B represented by a red signal). Mild regurgitation could be seen in the mitral and tricuspid valves (C)

Fig. 4.

The cardiac magnetic resonance of the proband II: 1. In the end-diastolic images of cine True-FISP sequence, the short axis view of middle segment (A), coronal view of the left ventricular outflow tract (B), and three-chamber view of the heart (C) showed that myocardial thickening of the subendocardial, basal and middle segment, anterior and anterior-lateral wall of LV. The cardiac trabeculae increased and disordered, showing a reticular/palisade shape (yellow arrow). The maximum thickness ratio of the noncompacted layer to compacted layer (N/C = D2/D1) was between 2.25 and 2.67 in different sections. Deep recess was found among the trabeculae, and the communication existed between trabecular recess and the left ventricular cavity. The interventricular septum was thickened (green arrow) about 18 mm, and the inferior wall of LV became thinner (red arrow). The short-axis view in the middle segment (D) of the T2W-TIRM sequence showed thickening of the anterior and anterior-lateral wall of LV, increased signal intensity in the subendocardial region due to slow blood flow in trabecular recess (yellow arrow), localized thinning of the lateral-inferior wall (red arrow), and general thickening of the ventricular septum (green arrow). The short axis (E) and four-chamber (G, H) views of the first-pass enhancement sequence showed that the early enhancement signal of trabecular recess in the anterior and anterior-lateral wall of LV was consistent with that of the heart cavity (yellow arrow), indicating that there were flowing blood component in it. The short axis (F) and four-chamber (I) views of PSIR-LGE showed extensive abnormal enhancement in the lateral wall of LV (yellow arrow) and abnormal enhancement in the interventricular septum (green arrow). T1W showed no abnormal fat depositing signal in left and right ventricles (blue arrow). Yellow arrow: thickened lateral-anterior wall. Red arrow: thinned lateral wall. Green arrow: thickened interventricular septum. Blue Arrow: normal right ventricular wall

I: 1 (father of II: 1) suffered from hypertension and stroke. He was persistently laid in bed for three years and subsequently died at the age of 67 years. I: 2 (mother of II: 1) died of SCD induced by acute myocardial infarction on the way to the hospital at 73 years old. We could not receive clinical information and blood samples of I: 1 and I: 2. The echocardiograms of II: 2 and II: 3 were normal. No characteristic change related to CMs was observed in the ECGs of II: 2 and II: 3 (Fig. 2G–H).

Genetic screening

We conducted genetic screening for the proband (II: 1) by target capture sequencing, and the rest of the family members were subjected to Sanger sequencing. The genetic screening revealed that the proband (II: 1) carried 10 exonic variants (Table 2), including two variants of DSC2 p.K47Rfs*2 (NM_004949: EX2/CDS2: c.140_147delAACTTGTT) and DSC2 p.I520T (NM_004949: EX11/CDS11: c.1559T>C), which were located in chromosome 18. The local and 1000 Genomes Project database frequency of DSC2 p.K47Rfs*2 and p.I520T was less than 0.001. DSC2 p.K47Rfs*2 was not detected in gnomAD exomes combined population. Desmocollin2 encoded by the DSC2 gene was an important component for desmosome assembly. Abnormal desmocollin2 caused the dysfunction of cell–cell adhesions and intercellular gap junctions, failing to hold together the cardiomyocytes, fibrofatty myocardial replacement, cardiac conduction delay, mechanically ventricular dysfunction and arrhythmias [23]. According to the protein reference sequence, DSC2 p.K47Rfs*2 converted the 47^th amino acid (AA) from lysine to arginine and led to a premature termination codon at the 48^th AA, which was therefore considered as frameshift and truncated mutation. This phenomenon caused the interrupting protein synthesis at the cadherin pro domain and loss of protein structure, including extracellular domains 1–4, extracellular anchor, a transmembrane domain, intracellular anchor, intracellular cadherin-like sequence, resulting in truncated protein without normal function (Fig. 1C). Based on the ACMG/AMP guidelines [14], the null variant (e.g., frameshift mutation) in a gene where the loss of function is a known disease mechanism was classified as PVS1, suggesting strong evidence of pathogenicity. Therefore, DSC2 p.K47Rfs*2, as a truncated and loss-of-function mutation, served as PVS1. DSC2 p.I520T (rs561310777) was demonstrated to be benign or likely benign by Clinvar database and the CHEO Genetics Diagnostic Laboratory in Children’s Hospital of Eastern Ontario (https://www.ncbi.nlm.nih.gov/clinvar/variation/155783/). The MAF of DSC2 p.I520T was 0.02% and not fulfilled with the criteria of the vast majority of reported pathogenic variants (MAF < 0.01%). Additionally, according to the analysis of the UCSC Genome Browser, the amino acid site of DSC2 p.I520 is not conserved in several species (Fig. 1D). Based on the genotype of II: 1, II: 2 did not carry heterozygous DSC2 p.K47Rfs*2 or p.I520T, whereas II: 3 with normal electrocardiogram and echocardiography only carried the heterozygous DSC2 p.I520T (Fig. 1A and B), indicating that these two variants were not linked on the same chromosome, but located on the homologous chromosomes, respectively. The variants of CACNA1C, COL5A1, GDF1, HTRA1, MEF2A, TSPYL1, and TTN were classified as benign or likely benign by the Clinvar database and ACMG guideline algorithm. Recently, no study confirmed that ELN variants cause CMs. The variant of ELN p.T248S was predicted to be tolerated/benign by SIFT and MetaSVM algorithms.

Table 2.

Predisposing analysis of genetic variants suspected to arrhythmia and cardiomyopathies for II: 1

Chr	Gene	Transcript	Zygosity	RS-ID	1000G	Local Fre	GnomAD	SIFT	PolyPhen	MetaSVM	Clinvar	ACMG classification
chr12	CACNA1C	NM_001129827, c.5753C>T, p.T1918M	Het	rs201777030	0	A	0.0011	0.17 (T)	0.60 (P)	T	B	US
chr9	COL5A1	NM_000093, c.61C>T, p.P21S	Het	rs548525119	0	A	0.0011	0.43 (T)	0.00 (B)	T	B	B
chr18	DSC2	NM_004949, c.1559T>C, p. I520T	Het	rs561310777	0	A	0.0002	0.00 (D)	0.47 (P)	T	B	US
chr18	DSC2	NM_004949, c.140_147delAACTTGTT, p. K47Rfs*2	Het	–	0	A	–	–	–	–	–	LP
chr7	ELN	NM_000501, c.742A > T, p. T248S	Het	–	0	A	0.000004064	0.35 (T)	0.97 (P)	T	–	US
chr19	GDF1	NM_001492, c.470_471insGGC	Het	rs571387097	0	A	0.038	–	–	–	B	LB
chr10	HTRA1	NM_002775, c.59C > T, p.A20V	Het	rs369149111	0	A	0.0207	0.53 (T)	0.00 (B)	T	B	B
chr15	MEF2A	NM_005587, c.1234_1236delCAG	Het	rs373652230	0	A	0.1518	–	–	–	B	B
chr6	TSPYL1	NM_003309, c.528_529insGTG	Hom	rs397735194	0	A	–	–	–	–	–	B
chr2	TTN	NM_001267550, c.36655T>G, p. L12219V	Hom	rs139508281	0	A	0.0954	–	0.00 (U)	T	B	B

Chr: chromosome. Fre: frequency. Het: heterozygosis. Hom: homozygosis. GnomAD: frequency of existing variant in gnomAD exomes combined population. Local Fre: frequency information about this SNP in sequencing samples of over 200 normal people collected locally. Local frequency: 0–0.01 = A; 0.01–0.05 is B (including 0.01 and 0.05); 0.05–1 is C. P: possibly damaging; T: tolerated; U: unknown. 1000G: 1000 Genomes Project databases (2014version). B: benign. D: deleterious. US: uncertain significance. LB: likely benign. LP: likely pathogenic. –, no report

Literature review of LVNC

We searched the NCBI database for studies with the theme of “left ventricle noncompaction” on June 13, 2021. We summarized the genes and their mutations associated with LVNC, which were predicted as likely pathogenic and pathogenic by ≥ 2 predicting algorithms, familial cosegregation validation, and molecular and/or animal/cell experiments, as shown in Table 3. Results showed that MYH7, MYBPC3, TPM1, TAZ, TTN, and NONO genes were the most common genes causing LVNC. LVNC caused by MYH7 and MYBPC3 mutations often complicated congenital heart diseases (CHD), such as atrial septal defect, ventricular septal defect, Ebstein, tetralogy of Fallot, patent ductus arteriosus, patent foramen ovale, and aortic hypoplasia. Some cases occurred with thromboembolism. Recently, LVNC induced by DES and DSP mutations was common and young-onset with HCM, DCM, ACM, myocarditis and HF, complicating ventricular and atrial tachycardias, and even needed therapy of heart transplantation in some cases. LVNC was associated with FBN1 mutation combined with DCM and Marfan syndrome. LVNC induced by HCN4 and EMD mutations complicated sick sinus syndrome (SSS), AF, atrial standstill, and interventricular block. Additionally, the LVNC induced by EMD mutation was combined with DCM. The LVNC caused by RYR2, KCNQ1, and KCNH2 mutations occurred with catecholamine-sensitive VT, long QT syndrome (LQTs), torsade de pointes, and ventricular fibrillation. In contrast, the LVNC result from SCN5A mutation complicated SSS, AF, LQTs, Wolff–Parkinson–White syndrome, VT, and atrioventricular block. Some genes led to LVNC and caused complex and critical clinical disease syndromes, such as Rubinstein–Taybi syndrome (i.e., ABCC9 gene), Ehlers–Danlos syndrome (i.e., COL3A1 gene), Emery–Dreifuss muscular dystrophy (i.e., EMD gene), Danon disease (i.e., LAMP2 gene), intellectual disability syndrome (i.e., NONO gene), Sotos syndrome (i.e., NSD1 gene), LEOPARD syndrome (i.e., PTPN11 gene), Coffin-Lowry syndrome (i.e., RPS6KA3 gene), Cornelia de Lange syndrome (i.e., SMC1A gene), Barth syndrome (i.e., TAZ gene), and Holt–Oram syndrome (i.e., TBX5 gene). Additionally, ARFGEF2, MIPEP, NONO, SH2B1, and TMEM70 led to LVNC complicating developmental delay. The deletion of one of these genes, including FKBP12, JARID2, NUMB, and PLZND1, induced LVNC by affecting the activity of the Notch signaling pathway in animal models, which had not been discovered in clinical cases until now. For these genes from Table 3, only ACTC1, ACTN2, DTNA, LDB3, MIB1, MYBPC3, MYH7, PRDM16, TNNT2, and TPM1 were reported to be associated with LVNC in the OMIM database (Table 4).

Table 3.

The detailed mutations and their clinical characteristics associated with left ventricular noncompaction

Gene	Mutation	Sex	Aged	LVNC	HCM	DCM	ACM	RCM	HF	SCD/VF	CTR	MA	Other	FV	FA
ABCC9	NM_005691, c.3594G>A, p.M1198I, rs199900459	M	32	+	−	−	−	−	−	−	−	−	Rubinstein–Taybi syndrome	−	−	[58]
ACTC1	NM_005159.4, c.62C>T, p.A21V	M	10 y	+	+	−	−	−	−	+	−	−	Transmural crypts	+	−	[59]
ACTC1	NM_005159.4, c.301G>A, p.E99K	M	11 y	+	+	−	−	−	−	−	−	−	−	+	+	[60]
ACTC1	NM_005159.4, c.478G>A, p.E101K	M	15 y	+	+	−	−	−	+	+	+	−	−	+	−	[61-64]
ACTC1	NM_005159.4, c.659A>C, p.Y220S	M	3 y	+	−	−	−	−	−	−	−	−	VT	−	−	[65]
ACTC1	NM_005159.4, c.692C>G, p.T231R	M	11 y	+	−	−	−	−	−	−	+	−	−	−	−	[65]
ACTC1	NM_005159.4, p.I289T	F	9 m	+	−	−	−	+	+	−	+	−	ASD	+	−	[66]
ACTC1	NM_005159.4, c.886T>C, p.Y296H	−	13 y	+	+	+	−	−	−	−	−	−	−	−	−	[67]
ACTC1	NM_005159.4, c.986T>C, p.I329T	F	48 y	+	−	−	−	−	−	+	−	−	VF, AF, IVB	+	−	[68]
ACTC1	NM_005159.4, c.670G>T, p.D224Y	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
ACTC1	NM_005159.4, c.281A>G, p.N94S	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
ACTC1	NM_005159.4, c.623G>A, p.R208H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
ACTN2	NM_001103.2, c.683T>C, p.M228T	M	30 y	+	+	−	−	−	+	−	−	−	AF, AVB, esophageal atresia, tracheal fistula, ASD	+	−	[69]
ACTN2	chr1: 236881238:CCT>– NM_001278343, p.L70del	F	9 y	+	+	−	−	−	−	+	−	−		+	−	[9]
ACTN2	NM_001103.3, c.668T>C, p.L223P	M	15 y	+	+	+	−	−	+	−	−	−	−	+	−	[70]
ANK2	NM_001148.4, c.11150T>A, p.I3717N	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
ANK2	NM_001148.4, c.9145C>T, p.R3049W	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
ALPK3	NM_020778, c.639G>A, p.W213X	M	34 w	+	+	+	−	−	+	−	−	−	PFO, VSD	+	−	[71]
ARFGEF2	NM_006420.2, c.5126G>A, p.W1709X	F	10 y	+	−	−	−	−	−	−	−	−	Movement disorder, developmental delay and microcephaly	−	−	[72]
BAG3	NM_004281.3, c.465_466insGCG, p.A156dup	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
BRAF	chr7:140477829:->A, NM_004333, p.Q493H MYH6:chr14: 23858233:G>A, NM_002471, p.S1337L, rs758922922	M	9 y	+	+	+	−	−	+	−	−	−	AVB, SVT	−	−	[9]
BMP10	NM_014482.3, c.1219G>A, p.V407I	F	−	+	−	−	−	−	−	−	−	−	−	+	+	[73]
BMP10	deletion	−	−	+	−	−	−	−	−	−	−	−	−	−	+	[74]
CACNA2D1	g.81603880_81603881delAA, NM(-), NP(-), p.R652RfsX3 and RANGRF, NM(-), NP(-), p.P155S	F	1 m	+	−	−	−	−	+	+	+	−	Histiocytoid cardiomyopathy, WPW, arrhythmia storms	−	−	[75]
CASQ2	NM_001232.4, p.H244R	M	53 y	+	−	−	−	−	−	−	−	−	thrombus	+	−	[76]
CASZ1	NM(-), NP(-), c.2443_2459del, p.V1815PfsX14	M	11 m	+	−	+	−	−	+	−	−	−	−	−	−	[8]
CDK10	NM_052988.4, c.452T>C, p.L151P. Chromosome 16q24.3 deletion encompassing 9 genes: CDK10, CPNE7, DPEP1, CHMP1A, SPATA33, SPATA2L, VPS9D1, ZNF276,and FANCA	M	3 m	+	−	−	−	−	+	+	−	−	Partial agenesis of the corpus callosum, unilateral multicystic dysplastic kidney, a single central incisor with pyriform aperture stenosis	+	−	[77]
COL3A1	NM_000090.4, c.2959G>A, p.G987S	M	32 y	+	−	+	−	−	+	−	−	−	Vascular Ehlers-Danlos Syndrome, AF	−	−	[78]
DES	NM(-), NP(-), p.L69P	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[79, 80]
DES	NM_001927.3, NP(-), c.336_344del, p.Q113_L115del	M	13 y	+	+	+	−	−	+	+	+	−	VT, AVB	+	+	[81]
DES	NM(-), NP(-), p.R212Q	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[79, 80]
DES	NM(-), NP(-), p.A360S	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[79, 80]
DES	NM(-), NP(-), c. C1360T, p.R454W	F	11 y	+	−	+	−	−	+	−	+	−	Coronary artery dissection, AVB, AFL	+	−	[82]
DSC2	NM_004949, c.140_147del, p. K47Rfs*2	M	54 y	+	+	−	−	−	+	−	−	−	AF, VT	+	−	This study
DSC2	NM_024422.3, c.1448A>T, p.N483I	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
DSP	NM(-), NC_000006.11, c.1339C>T	M	37 y	+	−	+	+	−	+	+	−	−	VT, myocarditis	+	−	[83]
DSP	NM_004415.2, c.3035delA, p.D1012fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
DSP	NM(-), NP(-), c.5208delAG, p.G1737fsX1742	M	5 y	+	−	+	−	−	+	+	−	−	Palmoplantar keratoderma	+	−	[84]
DTNA	NM(-), NP(-), c.146A>G, p.N49S	M	39 y	+	−	+	−	−	+	−	−	−	−	+	+	[85]
DTNA	NM(-), NP(-), c. 362 C>T, p.P121L	F	2 d	+	−	−	−	−	+	+	−	−	PDA, AF, VSD	+	−	[86-88]
EMD	NM(-), NP(-), c.226-2A>C	M	16 y	+	−	+	−	−	−	−	−	−	SSS, PFO, AS, Emery-deifuss muscular dystrophy	+	−	[89]
EMD	NM(-), NP(-), c.1A>G, p.M1V	M	53 y	+	−	+	−	−	+	−	−	−	SSS, AF, AS	+	−	[89]
EMD	NM(-), NP(-), c.23C>T, p.S8L	M	65 y	+	−	+	−	−	−	−	−	−	AVB, VT	+	−	[89]
EMD	NM(-), NP(-), c.415delC, p.L39fsX98	M	13 y	+	−	+	−	−	−	−	−	−	SSS, AS	+	−	[89]
FBN1	NM(-), NP(-), c.1633 C>T	F	14 y	+	−	+	−	−	+	−	−	−	Marfan syndrome	−	−	[90]
FBN1	NM(-), NP(-), c.3173 G>T	F	20 y	+	−	+	−	−	+	−	−	−	Marfan syndrome	−	−	[90]
FBN1	NM(-), NP(-), c.6832 C>T	M	2 y	+	−	+	−	−	+	−	−	−	Shprintzen-Goldberg	−	−	[90]
FKBP12	deletion	−	−	+	−	+	−	−	−	−	−	−	VSD, CHD	−	+	[38, 39]
FKTN	NM(-), NP(-), c.536G>C, p.R179T	M	26 y	+	−	+	−	−	+	−	−	−	−	−	−	[91]
FLNC	NM_001458.4, c.1933_1935del, p.645del	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
FLNC	NM(-), NP(-), c.4997T>C, p.I1666T	M	37	+	−	−	−	−	−	−	−	−	AF	−	−	[92]
GATA4	NM(-), NP(-), c.778 C>T, p.A242V and PTEN: NM(-), NP(-), c.517C>T, p.R173C	M	19 y	+	−	−	−	−	−	−	−	−	−	+	+	[93]
HADHB	NM(-), NP(-), c.1109+243_1438-703del	−	Fetus	+	+	−	−	−	+	+	−	−	TFP deficiency, lactic acidosis, hypoketotic hypoglycemia, and neonatal death	+	−	[94]
HCN4	NM_005477.2, c.1123C>T, p.R375C	F	16 y	+	−	−	−	−	−	−	−	−	SSS, left atrial dilatation	+	+	[33, 95]
HCN4	NM_005477.2, c.1231C>G, p.L411V	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
HCN4	NM(-), NP(-), c.1241C>G, p.A414G	M	74 y	+	−	−	−	−	−	−	−	−	SSS, AF	+	+	[96]
HCN4	NM_005477.2, c.1403C>T, p.A468V	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
HCN4	NM_005477.2, c.1438G>T, p.G480C	M	−	+	−	−	−	−	−	−	−	−	SSS	+	−	[33]
HCN4	NM(-), NP(-), c.1441T>C, p.Y481H	F	53	+	−	−	−	−	−	−	−	−	SSS, AF	+	+	[96]
HCN4	g.73622060 G>A, NM_005477.2, c. 1444G>A, p.G482R	M	23 y	+	−	−	−	−	+	+	−	−	SSS	+	+	[33, 96-98]
HCN4	NM(-), NP(-), p.R483_V487del	F	47 y	+	−	−	−	−	−	−	−	−	SSS, AF,Thoracic aortic aneurysms	+	−	[99]
HCN4	NM_005477.2, c.2432G>A, p.G811E	F	6 m	+	−	+	−	−	+	−	−	−	VSD, IVB	+	+	[100]
HEY2	NM_012259, c.683C>T p.T228M	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
Jarid2	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD	−	+	[101]
KCNH2	NM_001204798, c.818 C>T, p.T273M	F	22 y	+	−	−	−	−	−	+	−	−	LQTs, Tdp, VT, VF	+	+	[102]
KCNQ1	NM(-), NP(-), c.817C>T, p.L273F	M	48 y	+	−	−	−	−	−	−	−	−	LQTs, VSD	+	−	[103]
KCNQ1	NM(-), NP(-), c.1831 G>T, p.D611T	F	5 y	+	−	−	−	−	−	+	−	−	LQTs, VT, VF, epilepsy	+	−	[104]
LAMP2	NM(-), NP(-), c.64+2T>A	F	23 y	+	−	+	−	−	+	−	−	−	VSD	+	−	[105]
LAMP2	NM_002294.2, c.987T>G, p.Y329X	M	21 y	+	−	−	−	−	−	−	−	−	Electrical myotonia, Danon disease	+	−	[106]
LDB3	NM_007078.2, c.608C>T, p.S203L	−	−	+	−	−	−	−	−	−	−	−	Congenital muscular dystrophy	−	−	[33]
LDB3	NM_007078.2, c.625G>C, p.E209Q	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
LDB3	NM(-), NP(-), c.163G>A, p.V55I	F	14 y	+	−	+	−	−	−	−	−	−	−	−	−	[88]
LDB3	NM(-), NP(-), c.349G>A, p.D117N	M	33 y	+	+	+	−	−	−	−	−	−	IVB	−	+	[107, 108]
LDB3	NM(-), NP(-), c.587C>T, p.S196L	M	40 y	+	+	+	−	−	+	+	−	−	−	+	+	[88, 109-111]
LDB3	NM(-), NP(-), c.1876G>A, p.D626N	M	13 y	+	−	−	−	−	−	+	−	−	WPW	+	−	[86, 88]
LMNA	NM(-), NP(-), c.1608+5G>C and LDB3: NM(-), NP(-), p.D117N	M	30 y	+	+	+	−	−	+	+	−	−	Limb girdle muscular dystrophy, VT, AF, CAVB	+	−	[76]
LMNA	NM(-), NP(-), c.1968+26A>G and TAZ: NM(-), NP(-), p.F128S	M	57 y	+	−	−	−	−	−	+	−	−	−	+	−	[76]
LMNA	NM_170707.2, c.738delG, p.Q246fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
LMNA	NC_000001, c. T1334A, p.V445E	M	23 y	+	−	−	−	−	−	+	−	−	VT/VF	+	+	[112]
LMNA	NM(-), NP(-), c.1930C>T, p.R644C	F	2 y	+	−	+	−	−	−	−	−	−	VSD, dysmorphism, multicystic and dysplastic kidney	+	−	[113, 114]
MEF2A	NM(-), NP(-), p.R17X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[80]
MIB1	NM(-), NP(-), c.1587C>T, p.R530X	−	−	+	−	−	−	−	−	−	−	−	−	+	+	[115]
MIB1	NM(-), NP(-), c.2827G>T, p.V943F	−	−	+	−	−	−	−	−	−	+		−	+	+	[115]
MIB2	NM_080875, c.2225T>G, p.V742G	F/M	−	+	−	−	−	−	−	−	−	−	Menetrier-like gastropathy	+	+	[116]
MIB2	NM_080875, c.2950G>C, p.V984L	F	−	+	−		−	−	−	−	−	−	Menetrier-like gastropathy	+	+	[116]
MIPEP	NM_005932, c.1745T>G, p.L582R and c.212T>A, p.L71Q	M	5.5 m	+	−	−	−	−	−	+	−	−	WPW, seizures, hypotonia, developmental delay, respiratory chain disorder	+	+	[117]
MIPEP	NM_005932, c.916C>T, p.L306F and c.1804G>T, p.E602X	F	11 m	+	−	+	−	−	−	+	+	+	Developmental delay, metabolic myopathy, diffuse neuronal loss, eosinophilic esophagitis	+	+	[117]
MMACHC	NM(-), NP(-), c.271dupA	F	35 w	+	−	−	−	−	−	+	−	−	Intracellular vitamin B12 disorder	−	−	[118]
MYBPC3	NM(-), NP(-), c.68G>A, p.G5R	M	20 y	+	−	−	−	−	−	−	−	−	−	−	−	[119]
MYBPC3	NM(-), NP(-), p.G148R	M	30 y	+	+	+	−	−	+	+	−	−	TOF, mesenteric thrombosis, myelofibrosis	+	−	[76]
MYBPC3	NM_000256.3, c.532G>A, p.V178M	−	−	+	+	−	−	−	−	−	−	−	−	−	−	[33]
MYBPC3	NM(-), NP(-), p.A216T and ACTC1: NM(-), NP(-), 22C>T	M	50 y	+	−	−	−	−	+	−	−	−	VT	+	−	[76]
MYBPC3	NM(-), NP(-), c.1523GA, p.G490R	M	32 y	+	−	−	−	−	−	−	−	−	−	+	−	[119]
MYBPC3	NM_000256.3, c.1504C>T, p.R502W	F	19 y	+	+	−	−	−	−	−	−	−	−	+	−	[33, 120]
MYBPC3	NM(-), NP(-), p.R502Q and p.R943X	M	−	+	+	−	−	−	−	+	+	−	−	+	−	[121]
MYBPC3	NM(-), NP(-), c.2373dup, p.W792fs	F	7 w	+	+	+	−	−	−	+	−	−	PFO and mitral valve insufficiency	+	−	[122]
MYBPC3	NM(-), NP(-), c.2460C>T, p.R820W	F	43 y	+	+	+	−	−	−	+	−	−	AF	+	−	[123]
MYBPC3	NM_000256, NP_000247, c.2572A>C, p.S858R	F	2 m	+	−	+	−	−	+	−	+	+	−	+	+	[124]
MYBPC3	NM(-), NP(-), c.2673C>T, p.P873L	M	37	+	−	−	−	−	+	−	−	−	Pulmonary hypertension	−	−	[119]
MYBPC3	NM(-), NP(-), c.2827C>T, p.R943X	M	5 w	+	+	+	−	−	+	+	−	−	ASD	+	−	[122]
MYBPC3	NM(-), NP(-), c.2919-2920delCT, p.P955RfsX95	F	28	+	−	−	−	−	−	−	−	−	VT	−	−	[119]
MYBPC3	NM(-), NP(-), c.2864_2865del, p.P955fs and c.1513_1515del, p.K505del	F	5 m	+	+	+	−	−	+	+	−	−	−	+	−	[125]
MYBPC3	NM(-), NP(-), c.2909G>A, p.R970Q	M	−	+	−	−	−	−	−	+	−	−	−	+	−	[65]
MYBPC3	NM(-), NP(-), c.3408C>A, p.Y1136X and c.2373dupG	M	36 w	+	+	−	−	−	+	−	−	−	−	+	−	[126]
MYBPC3	NM(-), NP(-), 377delA, p.Q1259fs and c.3599T>C, p.L1200P	M	11 d	+	+	−	−	−	+	+	+	+	−	+	−	[127]
MLYCD	c.393_400del8	F	10 m	+	−	+	−	−	−	−	−	−	Malonyl coenzyme A decarboxylase deficiency	−	−	[128]
MYH6	NM_002471.3, c.50G>T, p.R17L	−	−	+	−	−	−	−	−	−	−	−	CHD	−	−	[33]
MYH6	NM_002471.3, c.1793dupA, p.N598fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYH6	NM_002471.3, c.4828C>T, p.R1610C	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYH7	NM_000257, c.130C>T, p.Q44X and c.5029C>T, p.R1677C	M	32 y	+	−	−	−	−	+	−	−	−	Ebstein	+	−	[124]
MYH7	NM_000257, c.379C>A, p.P127T	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYH7	NM_000257, c.464_466del, p.delF155	M	8 y	+	−	−	−	−	−	−	−	−	ASD, Ebstein	−	−	[68]
MYH7	g.23901862T>G, NM_000257, p.Q163P	−	−	+	+	−	−	−	−	−	−	−	−	+	−	[129]
MYH7	NM_000257, c.801_803delGAC, p.D239del	M	65 y	+	−	−	−	−	+	−	−	−	AVB	−	−	[62]
MYH7	NM_000257, c.814G>A, p.R243H	M	25 y	+	−	−	−	−	+	−	+	−	AF	+	−	[62]
MYH7	NM_000257, c.745C>G, p.R249G	F	35 y	+	−	−	−	−	+	−	−	−	IVB	+	−	[68]
MYH7	NM_000257, c.840T>C, p.F252L	M	58 y	+	−	−	−	−	+	+	−	−	NSVT	−	−	[62]
MYH7	NM_000257, p.R281T	−	−	+	−	−	−	−	−	−	−	−	Ebstein, CHD	+	−	[130]
MYH7	NM_000257, p.Y283D	F	49 y	+	−	−	−	−	−	−	−	−	Ebstein, ASD, VSD, CHD	+	−	[130, 131]
MYH7	NM_000257, c.847T>C, p.Y283H	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[65]
MYH7	NM_000257, p.L301Q	M	12 y	+	−	−	−	−	+	−	−	−	Ebstein	+	−	[76, 130]
MYH7	NM_000257, p.Y350D	−	−	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[130]
MYH7	NM_000257, p.E1350del	F	32 y	+	−	−	−	−	+	−	−	−	Aortic insufficiency	+	−	[76]
MYH7	NM_000257, p.Y350N	F	26 y	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[131]
MYH7	NM_000257, c.1085T>G, p.M362R	F	infant	+	−	−	−	−	−	−	−	−	Ebstein, ASD, VSD	+	−	[132, 133]
MYH7	NM_000257, c.1106G>A, p.R369Q	F	8 m	+	−	+	−	−	+	−	−	−	−	+	−	[127, 68]
MYH7	NM_000257, p.L390P	M	59 y	+	−	−	−	−	−	−	−	−	Ebstein, PFO, AF, CHD	−	−	[131, 130]
MYH7	NM_000257, c.1207C>T, p.R403W and c.1000–1G>A	M	14 y	+	+	−	−	−	−	+	−	−	VF	+	−	[124]
MYH7	NM_000257, p.K1459N	−	−	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[130]
MYH7	g:23897795G>C, NM_000257, c. 1492C>G, p.Q498E	M	19 y	+	−	−	−	−	−	−	−	−	−	+	−	[134]
MYH7	NM_000257, c.1678T>G, p.M531R	F	14 y	+	−	+	−	−	+	+	−	−	−	+	+	[135, 136]
MYH7	NM_000257, p.D545N and p.D955N	M	35 y	+	−	−	−	−	+	−	−	−	Thrombus	+	−	[76]
MYH7	g.23896462G>A, NM_000257, p.S648L	−	−	+	−	+	−	−	−	−	−	−	−	+	−	[129]
MYH7	NM_000257, p.L658V	M	61 y	+	+	−	−	−	−	−	−	−	−	−	−	[76]
MYH7	NM_000257, c.A2010_G2031del, p.R671_E677del	M	11 y	+	−	−	−	−	+	−			VSD	−	−	[137]
MYH7	g.23895236T>C, NM_000257, p.E700G	−	−	+	+	−	−	−	−	−	−	−	−	+	−	[129]
MYH7	NM_000257, c.2155C>T, p.R719W	M	29 y	+	+	−	−	−	+	+	−	−	−	+	−	[138]
MYH7	NM_000257, c.2419C>G, p.R807G	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYH7	NM_000257, p.I818N	M	21 y	+	+	−	−	−	−	+	−	−	−	+	−	[76]
MYH7	NG_016984.1, p.R890C	F	1 m	+	−	+	−	−	+	−	−	−	PDA, PFO	+	−	[139]
MYH7	NM_000257, p.C905R	M	30 y	+	−	+	−	−	−	−	−	−	Cardiac valvular disease	+	−	[140]
MYH7	NM_000257, c.2785G>A, p.E929K	M	42 y	+	−	+	−	−	+	+	−	−	VT, IVB	+	−	[68]
MYH7	NM_000257, c.3586C>T, p.H1196Y	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYH7	NM_000257, p.1220delE	M	35 y	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[130, 131]
MYH7	NM_000257, c.3830G>C, p.R1277P	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYH7	NM_000257, c.3748C>T, R1250W	M	55 y	+	+	+	−	−	+	−	+	−	−	+	−	[127]
MYH7	NM_000257, p.R723G and p.S1335L	M	22 y	+	+	−	−	−	−	+	+	−	−	+	−	[121]
MYH7	NM_000257, c.4161C>T, p.R1359C	M	29 y	+	−	−	−	−	+	−	−	−	AF	−	−	[62]
MYH7	NM_000257, c.4090G>C, p.A1364P	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[65]
MYH7	NM_000257, p.K1459N	F	58 y	+	−	−	−	−	−	−	−	−	Ebstein, SVT	−	−	[131]
MYH7	NM_000257, p.Y1488C	M	41 y	+	−	−	−	−	+	−	−	−	−	+	−	[76]
MYH7	NM_000257, c.4588C>T, p.R1530X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYH7	NM_000257, p.E1573K	F	33 y	+	−	−	−	−	−	−	−	−	Ebstein, VSD	+	−	[130, 131]
MYH7	NM_000257, c.5030G>A, p.R1677H	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[65]
MYH7	NM_000257, c.5382G>A, p.A1766T	M	20 y	+	−	−	−	−	−	−	−	−	−	−	−	[62]
MYH7	NM_000257, c.5401G>A, p.E1801K	M	25 y	+	−	−	−	−	−	−	−	−	AVB, neurological deficits, Laing distal myopathy	+	−	[141]
MYH7	NM_000257, c.5566G>A, p.E1856K	F	37 y	+	−	+	−	−	+	+	−	−	VF, distal myopathy	+	−	[142]
MYH7	NM_000257, p.N1918K	M	5 y	+	−	−	−	−	−	−	−	−	Ebstein, aorta coarctation	+	−	[131, 130, 76]
MYH7	NM_000257, p.R1925G	F	50 y	+	−	−	−	−	+	+	−	−	−	+	−	[76]
MYH7	NM_000257, c.8183G>C	M	14 y	+	−	−	−	−	−	−	−	−	−	+	−	[62]
MYLK2	NM_033118.3, c.1754T>A, p.I585N	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYLK2	NM_033118.3, c.1658G>A, p.R553H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
MYOT	NM_000257, c.179C>T	M	72 y	+	−	−	−	−	−	−	−	−	Myopathy	−	−	[143]
MYPN	NM_032578.2, c.3457G>A, p.G1153R	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
NEBL	NM_006393.2, c.2747C>T, p.P916L	M	37 y	+	−	+	−	−	+	−	−	−	VT	−	−	[144]
NKX2.5	NM(-), NP(-), p.K183N	F	30 y	+	−	+	−	−	+	+	−	−	ASD, VF	+	−	[145]
NKX2.5	NM(-),NP(-), c.512InsGC, p.170X	M	−	+	−	−	−	−	−	+	−	−	ASD, conduction defects,	+	+	[146]
NKX2.5	NM_004387.3, c.604C>G, p.L202V	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
NEXN	NM_144573.3, c.2012T>C, p.I671T	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
NEXN	NM_144573.3, c.1396A>C, p.K466Q	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
NNT	NM_012343, c.638_639insT, p.R213fs	−	−	+	−	+	−	−	+	−	+	+	−	+	+	[129]
NONO	NM_001145408.1, c.154+9A>G. MYH6: NM_002471.3, c.718G>A, p.D240N	−	Fetus	+	−	−	−	−	−	−	−	−	Mitral valve dysplasia, and aorta hypoplasia	+	+	[147]
NONO	NM_001145408, c.1171+1G>T	M	17 y	+	−	−	−	−	−	−	−	−	Intellectual disability syndrome	−	−	[148]
NONO	NM_001145408, c.1171+1G>A	M	4 y	+	+	−	−	−	−	−	−	−	Intellectual disability syndrome	−	−	[149, 150]
NONO	NM_001145408.1, the first three coding exons and 19 kb of sequence upstream of the transcriptional start site	M	1 m	+	−	−	−	−	+	+	+	−	PFO, Ebstein, developmental delay, encephalopathy, seizures and dysautonomia, cerebellum dysplasia	+	−	[151]
NONO	NM_001145408, c.154+5_154+6delGT, p.N52SfsX6	M	2 y	+	−	+	−	−	+	−	−	−	Ebstein, PFO, intellectual disability syndrome	+	−	[152]
NONO	NM_001145408.1, c.246_249del, p.P83TfsX7	M	fetus	+	−	−	−	−	−	−	−	−	Ebstein, PS, VSD, VSD, PLSVA, cardiovascular hypoplasia or transposition	+	−	[153]
NONO	NM_001145408, c.550C>T, p.R184X	M	2 y	+	−	+	−	−	−	−	−	−	ASD, VSD, PDA, aortic dilatation, intellectual disability syndrome	−	−	[149, 150]
NONO	NM_001145408, c.1093C>T, p.R365X	M	10 y	+	+	+	−	−	+	−	−	−	RVH, ASD, VSD, PDA, Intellectual disability syndrome	−	−	[151]
NONO	NM_001145408, c.1394dupC, p.N466KfsX13	M	5 y	+	−	−	−	−	−	−	−	−	ASD, VSD, PDA, intellectual disability syndrome	−	−	[151]
NONO	NM_001145408.1, c.471del, p.Q157HfsX18	M	fetus	+	−	−	−	−	−	+	−	−	Ebstein, PS, ASD, VSD, aortic arch variation, endocardial fibroelastosis, PFO, corpus callosum hypoplasia			[153]
NRG1	NM(-), NP(-), c.661G>A, p.W143X	M	−	+	−	−	−	−	−	−	−	−	−	+	+	[73]
NSD1	NM(-), NP(-), c.6218_6219insG	M	11 y	+	−	+	−	−	−	+	−	−	Sotos syndrome	−	−	[1]
NSD1	NM(-), NP(-), c.2604_2605dupTT	F	6 y	+	+	−	−	−	−	−	−	−	Sotos syndrome	−	−	[1]
NUMB	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD	−	+	[154]
OBSCN	g.228552766_228552767delinsG, NM(-), NP(-), p.T7266RfsX53	M	56 y	+	−	−	−	−	−	−	−	−	−	−	−	[155]
OBSCN	g.228559442delC, NM(-), NP(-), p.S7947PfsX82, rs71180793	F	30 y	+	−	−	−	−	−	−	−	−	−	−	−	[155]
OBSCN	g.228562285G>C, NM(-), NP(-), c.25367-1G>C, rs55883237	M	39 y	+	−	−	−	−	−	−	−	−	−	−	−	[155]
PDLIM3	NM_014476.4, c.742C>T, p.R248C	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
PKP2	deletion	F	12 d	+	−	−	−	−	+	+	−	−	−	+	−	[50]
PKP2	NM_004572.3, c.2018G>A, p.G673D	−	−	+	−	−	+	−	−	−	−	−	−	−	−	[33]
PLEKHM2	NM(-), NP(-), c.2156_2157delAG, p.K645AfsX12	M	7 y	+	−	+	−	−	+	+	+	−	VT	+	+	[156]
Plxnd1	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD, aortic arch anomalies, persistent truncus arteriosus	−	+	[42]
PLN	NM(-), NP(-), p.R14del	F	48 y	+	−	−	−	−	−	−	−	−	MVT, thrombus	+	−	[76]
PRDM16	NM_022114.3, c.1047dupC, p.S350fsX48	M	4 m	+	−	+	−	−	−	−	−	−	−	+	−	[157]
PRDM16	g.3322083C>T, NC_000001.10, c.1057C>T, p.Q353X	−	31 w fetus	+	−	+	−	−	−	−	−	−	−	+	−	[158]
PTPN11	NM(-), NP(-), p.W279C	M	40 y	+	+	−	−	−	−	−	−	−	AF, LEOPARD syndrome	−	−	[159]
RBM20	NM_001134363, c.1901 G>T, p.R634L	F	39 y	+	−	−	−	−	−	+	+	−	TOF	+	+	[34]
RBM20	NM_001134363, c.1907G>A, p.R636H	F	11 y	+	−	+	−	−	+	−	−	−	−	+	−	[33, 160]
RBM20	NM_001134363, c.1909A>G, p.S637G	M	13 y	+	−	+	−	−	+	−	−	−	−	+	−	[160]
Rac1	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD, CHD	−	+	[161]
RPS6KA3	NM(-), NP(-), c.1000-2A>G	M	1 y	+	−	+	−	+	+	+	−	−	Coffin–Lowry syndrome	+	−	[162]
RYR2	deletion	F	20 y	+	−	+	−	−	−	+	−	−	AF, VF	+	−	[163-165]
RYR2	NM(-), NP(-), c.506G>A, p.R169Q	F	5 y	+	−	−	−	−	−	+	−	−	CPVT, VF	+	+	[30]
RYR2	NM_001035.2, c.169-?_c.273+?del	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[33]
RYR2	NM_001035.2, c.878A>C, p.Q293P	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
RYR2	NM_001035.2, c.6180G>T, p.Q2060H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
RYR2	NM_001035.2, c.13936G>C, p.D4646H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
RYR2	NM(-), NP(-), p.I4855M	F	10 y	+	−	−	−	−	−	+	−	−	CPVT, ASD	+	+	[166]
SCN5A	NM_198056.1, c.1141-3C>A	M	13 y	+	−	−	−	−	+	−	−	−	PVC, WPW	+	−	[167]
SCN5A	NM_198056.1, c.87G>A, rs6599230	M	43 y	+	−	−	−	−	−	−	−	−	PVC, LQTs	+	−	[167]
SCN5A	NM_198056.1, c.453C>T	F	1 w	+	−	−	−	−	+	−	−	−	PVC	+	−	[167]
SCN5A	NM_198056.1, c.1673A>G, p.H558R, rs1805124	M	13 y	+	−	−	−	−	+	−	−	−	PVC, WPW	+	−	[167]
SCN5A	NM_198056.1, c.3269C>T, p.P1090L, rs1805125	M	4 y	+	−	−	−	−	+	−	−	−	AF, SSS, PVC	+	−	[167]
SCN5A	NM_198056.1, c.3996G>A	M	0 y	+	−	−	−	−	+	−	−	−	AVB	−	−	[167]
SCN5A	NM_198056.1, c.5457T>C, rs1805126	F	5 y	+	−	−	−	−	+	−	−	−	PSVT, VT, AVB, LQTs, SSS, AF, WPW	+	−	[167]
SDHD	NM(-), NP(-), c.275A>G, p.D92G	M	neonate	+	+	−	−	−	−	+	−	−	Mitochondrial complex II deficiency	−	−	[168]
SH2B1	Deletion	M	18 d	+	−	−	−	−	−	−	−	−	Aorta stenosis, ASD, developmental delay	+	−	[169]
SLC39A8	Deletion	−	−	+	−	−	−	−	−	−	−	−	−	−	+	[170]
SMC1A	NM(-), NP(-), c.1636_1638delATT	F	21 m	+	+	−	−	−	−	−	−	−	Microform Cleft Lip, poor Vision, Cornelia de Lange Syndrome	+	−	[171]
STRA6	NM_022369.4, c.113+3_113+4del	−	Fetus (22 w)	+	−	−	−	−	−	−	−	−	Syndromic microphthalmia, interrupted aortic arch type A	+	−	[172]
TAZ	NM_000116.3, p.R94H	M	12 h	+	−	−	−	−	+	+	−	−	−	+	−	[173]
TAZ	NM_000116.3, intron1+9G>C	M	4 m	+	−	+	−	−	+	+	−	−	Barth syndrome	+	−	[174]
TAZ	NM_000116.3, c.IVS8-1G>C	M	3 m	+	+	+	−	−	+	+	−	−	−	+	−	[86] [88]
TAZ	NM_000116.3, IVS10+2T>A	M	8 m	+	−	−	−	−	+	+	−	−	Barth syndrome	+	−	[87, 110]
TAZ	NM_000116.3, c.109+1G>C	M	4 m	+	−	+	−	−	+	+	−	−	Barth syndrome	+	−	[175]
TAZ	NM_000116.3, c.777+2T>A	M	infant	+	−	+	−	−	+	+	−	−	Barth syndrome	−	−	[176]
TAZ	NM_000116.3, c.134_136delinsCC, p.H45PfsX38	M	1.0	+	−	−	−	−	+	+	−	−	Barth syndrome	+	−	[177]
TAZ	NM_000116.3, 158InsC, p.L53Pfs80X	M	19 y	+	−	−	−	−	−	−	−	−	Barth syndrome	−	−	[88]
TAZ	chrX:153641550:T>C, NM_000116, p.L82P	M	1 m	+	−	+	−	−	+	+	−	−	VT, VF	−	−	[9]
TAZ	NM_000116.3, p.C118R	−	5 m	+	−	−	−	−	+	+	−	−	−	−	−	[178]
TAZ	NM_000116.3, p.C118R and p.T352C	M	5 m	+	−	+	−	−	+	−	−	−	Barth syndrome			[87, 110]
TAZ	NM_000116.3, c.367C>T, p.R123X	M	20 y	+	−	−	−	−	−	+	−	−	Barth syndrome	+	−	[177]
TAZ	NM_000116.3, c.527A>G, p.H176R	M	3.0 y	+	−	−	−	−	+	+	−	−	Barth syndrome	+	−	[177]
TAZ	NM_000116.3, c.583G>T, p.G195X	M	45 y	+	−	+	−	−	+	−	+	−	AF, ASD, barth syndrome	+	−	[179]
TAZ	NM_000116.3, p.G197R	−	0 d	+	−	−	−	−	+	+	−	−	−	−	−	[178]
TAZ	NM_000116.3, c.646G>A, p.G216R	M	14 m	+	−	−	−	−	+	−	−	−	Barth syndrome	+	+	[180]
TAZ	chrX:153648583:A>insAA, NM_000116, p.Y227_F228delinsX	M	6 m	+	+	+	−	−	+	+	−	−	−	−	−	[9]
TAZ	NM_000116.3, c.710_711delTG, p.V237AfsX73	M	6.5 y	+	−	−	−	−	−	+	−	−	Barth syndrome	+	−	[177]
TAZ	chrX: 153649305:G>-, NM_000116, p.A281QfsX58	M	1 y	+	+	+	−	−	−	+	−	−	−	−	−	[9]
TBX5	NM_000192.3, c.510+5G>T	F	34 y	+	−	−	−	−	−	−	−	−	SSS, AF, ASD, Holt-Oram syndrome	+	−	[181]
TBX5	NM_000192.3, p.S36Tfs*25	F	49 y	+	−	+	−	−	−	−	−	−	SSS, Holt-Oram syndrome	+	−	[181]
TBX5	NM(-), NP(-), c.791G>A, p.R264K	M/F	3 m	+	−	+	−	−	+	+	−	−	Embolism, VSD	+	+	[182]
TBX20	NM(-), NP(-), c.785C>T, p.T262M	F	−	+	−	−	−	−	−	−	−	−	−	+	+	[183]
TBX20	NM(-), NP(-), c. 951C>A, p.Y317X	M/F	−	+	−	+	−	−	−	−	+	−	−	+	+	[183]
TMEM43	NM_024334.2, c.317A>G, p.Y106C	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TMEM70	NM_017866.5, c.141delG, p.P48Rfs*2, and c.316+1G>A	M	36 w	+	+	−	−	−	−	−	−	−	Developmental delay, undescended testicle	+	+	[184]
TNNC1	NM(-), NP(-), c.243G>C, p.M81I	F	5 m	+	−	−	−	−	−	−	−	−	−	+	−	[65]
TNNC1	NM(-), NP(-), c.281A>C, p.E94A	F	4 m	+	−	−	−	−	+	−	+	−	−	−	−	[65]
TNNC1	NM(-), NP(-), c.304C>T, p.R102C	F	12 y	+	−	−	−	−	−	−	+	−	−	+	−	[65]
TNNI3	NM_000363.4, c.575C>A, p.R192H	F	13 y	+	+	−	−	−	−	+			−	−	−	[185]
TNNT2	NM_001001430.1, c.?GAG>AAG, p.E96K	F	5 m	+	−	−	−	−	+	+	+	−	−	+	−	[186]
TNNT2	NM_000364.3, c.305G>A, p.R102Q	F	44 y	+	+	−	−	−	−	−	−	−	AF, IVB	+	−	[68]
TNNT2	NM(-), NP(-), p.D117N	F	45 y	+	+	−	−	−	−	−	−	−	SVT	+	−	[76]
TNNT2	NM_001001431, c.450C>T, p.R131W	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[62, 187]
TNNT2	NM(-), NP(-), p.K210del	M	14 y	+	−	+	−	−	+	−	+	−	−	+	−	[121]
TPM1	NM_00101805.1, c.41A>G, p.D14G	F	20 d	+	−	−	−	−	+	+	−	−	−	−	−	[65]
TPM1	NM(-), NP(-), c.109A>G, p.K37E	F	8 y	+	−	−	−	−	−	+	−	−	VF, SCD	+	−	[65, 188]
TPM1	NM_001018007, c.377C>G, p.L113V	F	22 w	+	−	−	−	−	+	+	+	+	Mitral valve insufficiency, pulmonary hypertension	+	−	[189]
TPM1	NM 001018005.1, c.475G>A, p.D159A	F	2 y	+	−	−	−	−	+	+	+	−	Ebstein	−	−	[190]
TPM1	NM_00101805.1, NP_001018005.1, c.533G>A, p.R178H	F	13 d	+	−	−	−	−	+	−	+	−	−	−	+	[65]
TPM1	NM(-), NP(-), c.765G>A, p.E192K	M	55 y	+	−	−	−	−	−	−	−	−	−	−	−	[119]
TPM1	NM_001018020.1, c.725C>T, p.A242V	M	45 y	+	−	+	−	−	−	+	−	−	VT, AF, IVB	+	−	[68]
TPM1	NM(-), NP(-), c.933A>G, p.K248E	M	63 y	+	−	−	−	−	+	−	−	−	−	+	−	[119]
TPM1	g.23857430C>C, NM(-), NP(-), p.D275H	−	−	+	−	+	−	−	−	−	−	−	−	+	−	[129]
TTN	NM(-), NP(-), c.533C>A, p.A178D	M	20 y	+	+	+	−	−	+	+	−	−	−	+	+	[191]
TTN	NM(-), NP(-), c.8858_8859del, p.F2953fs	M	17 y	+	−	−	−	−	+	−	−	−	−	+	−	[34]
TTN	NM_001256850.1, c.43360C>T, p.R14454X	−	−	+	−	−	−	−	−	−	−	−	CHD	−		[33]
TTN	NM_001256850.1, c.44248C>T, p.R14750X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TTN	NM_001256850.1, c.53947C>T, p.R17983X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TTN	NM(-), NP(-), c. 54668G>A, p.G18223D	F	30 y	+	−	−	−	−	−	−	−	−	Embolism	+	−	[34]
TTN	NM_001256850.1, c.61961G>A, p.W20654X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TTN	NM_001256850.1, c.64100_64101insTTGA, p.D21368X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TTN	NM_001256850.1, c.80845C>T, p.R26949X	−	−	+	−	−	−	−	−	−	−	−	CHD	−	−	[33]
TTN	NM(-), NP(-), c.81307_81310del, p.I27103fs	M	16 y	+	−	−	−	−	+	+	+	−	AF, VT	+	−	[34]
TTN	NM_001256850.1, c.82724delA, p.N27575fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TTN	NM(-), NP(-), c.83889_83890del, p.Y27963fs	M	52 y	+	−	−	−	−	+	−	+	−	AF, VT	+	−	[34]
TTN	chr2: 179425207: GGAACTGTAAATG>-, NM_001267550, p.28547QfsX12, rs762286447	M	1 y	+	−	+	−	−	+	−	−	−	AVB, ASD	+	−	[9]
TTN	NM_001256850.1, c.93376delA, p.R31126fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TTN	NM_001256850.1, c.98039_98040insTCAA, p.N32680fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]
TTN	NM(-), NP(-), c. 9388+1G>C, p.E2989EfsX4 and c. 102439T>C, p.W34072R	F	38 y	+	−	+	−	−	+	−	+	−	VSD, arthrogryposis multiplex congenital	+	−	[192]
YWHAE	NM(-), NP(-), c.-458G>T	M	2 w	+	−	−	−	−	−	+	−	−	Hypoplasia of the corpus callosum	+	+	[193]
Mitochondrial DNA
Met31	m. 3397A>G	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[194]
Met31	m. 3398T>C	M	35 y	+	−	−	−	−	−	−	−	−	−	−	−	[194]
ND1	m.3308T>C	F	6 y	+	−	+	−	−	−	−	−	−	Ebstein	+	+	[195, 196]

M: male. F: female. y: years. w: weeks. m: months. d: days. LVNC: left ventricular noncompaction. HCM: hypertrophic cardiomyopathy. DCM: dilated cardiomyopathy. ACM: arrhythmogenic cardiomyopathy. RCM: restricted cardiomyopathy. HF: heart failure. SCD: sudden cardiac death. FV: family verification. FA: functional analysis. CTR: cardiac transplantation. MA: mechanical assist. fs: frame-shift mutation. X: truncated mutation. VT: ventricular tachycardia. VF: ventricular fibrillation. MVT: ventricular tachycardia needed resuscitation. AVB: atria-ventricular block. AF: atrial fibrillation. AS: atrial standstill. IVB: intra-ventricular block. ASD: atrial septal defect. CHD: congenital heart disease. VSD: ventricular septal defect. SVT: supraventricular tachycardia. PFO: patent foramen ovale. TOF: fallot tetralogy. SVT: supraventricular tachycardia. PVC: premature ventricular contraction. LQTs: long QT syndrome. SSS: sick sinus syndrome. WPW: Wolff–Parkinson–White syndrome. TdP: torsade de pointes. CPVT: Catecholamine sensitive ventricular tachycardia. PDA: patent ductus arteriosus. PLSVA: persistent left superior vena cava. PS: pulmonary stenosis. RVH: right ventricular hypertrophy. −, not mentioned in the previous reports. +, mentioned/occurred in previous reports

Table 4.

The phenotypes of genes associated with left ventricular noncompaction in OMIM database

Location	Genes	Full name	Gene/locus MIM number	Phenotypes in OMIM
12p12.1	ABCC9	ATP binding cassette subfamily C member 9	601439	AF; DCM; hypertrichotic osteochondrodysplasia
15q14	ACTC1	Actin alpha cardiac muscle 1	102540	ASD; DCM; HCM; LVNC
1q43	ACTN2	Actinin alpha 2	102573	DCM; HCM; LVNC; myopathy
4q25-q26	ANK2	Ankyrin 2	106410	Cardiac arrhythmia; LQTs
15q25.3	ALPK3	Alpha kinase 3	617608	HCM
20q13.13	ARFGEF2	ADP ribosylation factor guanine nucleotide exchange factor 2	605371	Periventricular heterotopia with microcephaly
10q26.11	BAG3	BAG cochaperone 3	603883	DCM; myofibrillar myopathy
7q34	BRAF	B-Raf proto-oncogene, serine/threonine kinase	164757	Adenocarcinoma of lung, somatic; cardiofaciocutaneous syndrome; colorectal cancer, somatic; LEOPARD syndrome; melanoma, malignant, somatic; nonsmall cell lung cancer, somatic; Noonan syndrome
2p13.3	BMP10	Bone morphogenetic protein 10	608748	–
7q21.11	CACNA2D1	Calcium voltage-gated channel auxiliary subunit alpha2delta 1	–	–
1p13.1	CASQ2	Calsequestrin 2	114251	CPVT
1p36.22	CASZ1	Castor zinc finger 1	609895	–
2q32.2	COL3A1	Collagen type III alpha 1 Chain	120180	Ehlers–Danlos syndrome, vascular type; polymicrogyria with or without vascular type Ehlers–Danlos syndrome
2q35	DES	Desmin	125660	DCM; myofibrillar yopathy; Scapuloperoneal syndrome, neurogenic, kaeser type
18q12.1	DSC2	Desmocollin2	125645	ACM; mild palmoplantar keratoderma and woolly hair
6p24.3	DSP	Desmoplakin	125647	ACM; DCM; woolly hair and keratoderma; keratoderma and tooth agenesis; epidermolysis bullosa, lethal acantholytic; keratosis palmoplantaris striata II; Skin fragility-woolly hair syndrome
18q12.1	DTNA	Dystrobrevin alpha	601239	LVNC; CHD
Xq28	EMD	Emerin	300384	Emery-Dreifuss muscular dystrophy
15q21.1	FBN1	Fibrillin 1	134797	Acromicric dysplasia; ectopia lentis, familial; geleophysic dysplasia; marfan lipodystrophy syndrome; Marfan syndrome; MASS syndrome; Stiff skin syndrome; Weill–Marchesani syndrome
20p13	FKBP12	FKBP prolyl isomerase 1A	186945	–
9q31.2	FKTN	Fukutin	607440	DCM; muscular dystrophy-dystroglycanopathy
7q32.1	FLNC	Filamin C	102565	HCM; RCM; distal myopathy; myofibrillar myopathy
2p23.3	HADHB	Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta	143450	Trifunctional protein deficiency
15q24.1	HCN4	Hyperpolarization activated cyclic nucleotide gated potassium channel 4	605206	Brugada syndrome; SSS
6q22.31	HEY2	Hes related family bHLH transcription factor with YRPW motif 2	604674	–
6p22.3	JARID2	Jumonji and AT-rich interaction domain containing 2	–	–
8p23.1	GATA4	GATA binding protein 4	600576	Testicular anomalies with or without congenital heart disease; ASD; VSD; TOF
11p15.5-p15.4	KCNQ1	Potassium voltage-gated channel subfamily Q member 1	607542/604115	LQTs; SQTs; AF; Jervell and Lange–Nielsen syndrome; Beckwith–Wiedemann syndrome
7q36.1	KCNH2	Potassium voltage-gated channel subfamily H member 2	152427	LQTs
Xq24	LAMP2	Lysosomal associated membrane protein 2	309060	Danon disease
10q23.2	LDB3	LIM domain binding 3	605906	DCM; HCM; LVNC; myofibrillar myopathy
1q22	LMNA	lamin A/C	150330	DCM; RCM; Charcot-Marie-Tooth disease; Emery-Dreifuss muscular dystrophy; Heart-hand syndrome; Hutchinson-Gilford progeria; lipodystrophy; Malouf syndrome; mandibuloacral dysplasia; muscular dystrophy
15q26.3	MEF2A	Myocyte enhancer factor 2A	600660	Coronary artery disease
1p34.1	MMACHC	Metabolism of cobalamin associated C	609831	Methylmalonic aciduria and homocystinuria
18q11.2	MIB1	MIB E3 ubiquitin protein ligase 1	608677	LVNC
1p36.33	MIB2	MIB E3 ubiquitin protein ligase 2	611141	–
13q12.12	MIPEP	Mitochondrial intermediate peptidase	602241	Combined oxidative phosphorylation deficiency
11p11.2	MYBPC3	Myosin binding protein C3	600958	DCM; HCM; LVNC
16q23.3	MLYCD	Malonyl-CoA decarboxylase	606761	Malonyl-CoA decarboxylase deficiency
14q11.2	MYH7	Myosin heavy chain 7	160760	DCM; HCM; LVNC; laing distal myopathy; myopathy, myosin storage; Scapuloperoneal syndrome
20q11.21	MYLK2	Myosin light chain kinase 2	606566	HCM
5q31.2	MYOT	Myotilin	604103	Myofibrillar myopathy; myopathy, spheroid body
10p12.31	NEBL	Nebulette	605491	–
5q35.1	NKX2.5	NK2 homeobox 5	600584	ASD; AVB; conotruncal heart malformations; Hypoplastic left heart syndrome; hypothyroidism, congenital nongoitrous; TOF; VSD
1p31.1	NEXN	Nexilin F-actin binding protein	613121	DCM; HCM
5p12	NNT	Nicotinamide nucleotide transhydrogenase	607878	Glucocorticoid deficiency with or without mineralocorticoid deficiency
Xq13.1	NONO	Non-POU domain containing octamer binding	300084	Mental retardation
8p12	NRG1	Neuregulin 1	142445	Schizophrenia
5q35.3	NSD1	Nuclear receptor binding SET domain protein 1	606681	Sotos syndrome
1q42.13	OBSCN	Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF	–	–
4q35.1	PDLIM3	PDZ and LIM domain 3	–	–
12p11.21	PKP2	Plakophilin 2	602861	ACM
1p36.21	PLEKHM2	Pleckstrin homology and RUN domain containing M2	609613	–
3q22.1	PLXND1	Plexin D1	604282	–
6q22.31	PLN	Phospholamban	172405	HCM; DCM
1p36.32	PRDM16	PR/SET domain 16	605557	DCM; LVNC
12q24.13	PTPN11	Protein tyrosine phosphatase non-receptor type 11	176876	LEOPARD syndrome; leukemia, juvenile myelomonocytic, somatic; metachondromatosis; Noonan syndrome
10q25.2	RBM20	RNA binding motif protein 20	613171	DCM
Xp22.12	RPS6KA3	Ribosomal protein S6 kinase A3	300075	Coffin–Lowry syndrome; mental retardation
1q43	RYR2	Ryanodine receptor 2	180902	ACM; CPVT
3p22.2	SCN5A	Sodium voltage-gated channel alpha subunit 5	600163	Sudden infant death syndrome; AF; Brugada syndrome; DCM; LQTs; SSS; VF
11q23.1	SDHD	Succinate dehydrogenase complex subunit D	602690	Mitochondrial complex II deficiency; araganglioma and gastric stromal sarcoma; paragangliomas with or without deafness
16p11.2	SH2B1	SH2B adaptor protein 1	608937	–
4q24	SLC39A8	Solute carrier family 39 member 8	608732	Congenital disorder of glycosylation
Xp11.22	SMC1A	Structural maintenance of chromosomes 1A	300040	Cornelia de Lange syndrome; developmental and epileptic encephalopathy, with or without midline brain defects
15q24.1	STRA6	Signaling receptor and transporter of retinol STRA6	610745	Microphthalmia with coloboma; Microphthalmia, syndromic
X A7.3; X 37.95 cM	TAZ	Tafazzin	300394	Barth syndrome
12q24.21	TBX5	T-box transcription factor 5	601620	Holt–Oram syndrome
7p14.2	TBX20	T-box transcription factor 20	606061	ASD
3p25.1	TMEM43	Transmembrane protein 43	612048	ACM; Emery-Dreifuss muscular dystrophy
8q21.11	TMEM70	Transmembrane protein 70	612418	Mitochondrial complex V (ATP synthase) deficiency, nuclear type
3p21.1	TNNC1	Troponin C1, slow skeletal and cardiac type	191040	DCM; HCM
19q13.42	TNNI3	Troponin I3, cardiac type	191044	DCM; RCM; HCM
1q32.1	TNNT2	Troponin T2, cardiac type	191045	DCM; RCM; HCM; LVNC
15q22.2	TPM1	tropomyosin 1	191010	DCM; HCM; LVNC
2q31.2	TTN	Titin	188840	DCM; HCM; muscular dystrophy, limb-girdle; myofibrillar myopathy with early respiratory failure; salih myopathy; tibial muscular dystrophy, tardive
17p13.3	YWHAE	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	605066	–

LVNC: left ventricular noncompaction. HCM: hypertrophic cardiomyopathy. DCM: dilated cardiomyopathy. ACM: arrhythmogenic cardiomyopathy. RCM: restricted cardiomyopathy. AF: atrial fibrillation. ASD: atrial septal defect. CHD: congenital heart disease. VSD: ventricular septal defect. PFO: patent foramen ovale. TOF: fallot tetralogy. LQTs: long QT syndrome. SQTs: short QT syndrome. SSS: sick sinus syndrome. WPW: Wolff–Parkinson–White syndrome. CPVT: catecholamine sensitive ventricular tachycardia. VF: ventricular fibrillation. PDA: patent ductus arteriosus. –, not mentioned in OMIM database

Expression of DSC2

The western blot (Fig. 5) showed that the expressing level of functional desmocollin2 protein (~ 94kd) was lower in the proband than that in the healthy volunteer, indicating that DSC2 p.K47Rfs*2 remarkably and abnormally reduced the functional desmocollin2 expression in the proband.

Fig. 5.

The expression of desmocollin2. NS: normal control (the healthy volunteer). The samples of NS and DSC2 p.K47Rfs*2 were collected from the skin and subcutaneous tissue in the upper left limb of the healthy volunteer and the proband (II: 1)

Discussion

In our study, we have first discovered that the truncated mutation (p.K47Rfs*2) of DSC2 remarkably and abnormally reduced the functional desmocollin2 expression, as an important component of desmosome assembly, which may consequently induce rare overlap phenotypes of LVNC and HCM, complicating AF, VT, and HF.

LVNC is a rare primary CM and serves as a global cardiac disease induced by the arrest of normal embryogenesis of the endocardium and mesocardium that leads to prominent trabeculations and deep intertrabecular recesses within the LV wall communicating with the cavity, a thin compacted epicardial layer, and acquired ventricular wall remodeling [24]. The inferior and lateral walls of LV from the midcavity to the apex are the most commonly involved [10]. The Jenni and Petersen diagnosis criteria of LVNC are generally accepted and rely on imaging modalities, including echocardiography and CMRI, e.g., (1) bilayer myocardium with multiple, prominent trabeculations in the end-systole; (2) NC/C ratio of > 2:1 in echocardiography or > 2.3 in CMRI measured in the end-systole or end-diastole, respectively; and (3) communication with the intertrabecular space and deep intertrabecular recesses in the noncompaction layer [10, 11]. Based on previous studies [25] and our literature review, the LVNC prevalence is 0.05%–0.3% in an adult population undergoing echocardiography. LVNC may occur with congenital heart malformations, myopathies, neuromuscular and metabolic diseases, complicating developmental delay and intellectual disability. LVNC with HF, ventricular arrhythmias, and thromboembolic events show poor prognosis with an overall mortality rate of 5–12% per year [26]. As shown in the literature review in our study, once the cases occur with LVNC and malignant clinical syndromes, the prognosis is poor with high mortality in the fetus or infant. Some LVNC patients have a family history of LVNC and/or sudden death and recurrent VT despite therapy with multiple antiarrhythmic drugs. The ventricular arrhythmia ordinarily originates from bilateral ventricles. The substrate of ventricular arrhythmia in LVNC typically involves the mid-apical segment, septum, and lateral wall of LV. In contrast, focal PVCs commonly arise from LV basal-septal regions and/or papillary muscles, reflecting the distribution of noncompaction myocardial segments [27]. LVNC mostly affects the left ventricular muscle and serves as a primary and genetically heterogeneous CM, which the American Heart Association exists in sporadic and hereditary forms. Previous research showed that among LVNC cases, 52% are sporadic, 32% have a genetic cause, and an additional 16% have affected family members with negative genetic testing. Not all family members present with the same LVNC phenotype as some proband occurs with DCM, HCM, or SCD [28]. Potentially causative gene mutations responsible for LVNC are involved in the sarcomere, cytoskeleton, mitochondria, desmosome, and storage and ion channels implicated in other cardiac diseases [29–31]. According to previous studies and our literature review, MYH7, MYBPC3, TPM1, TAZ, TTN, and NONO genes are the most common pathogenic mutations in LVNC [28, 32, 33], which are not demonstrated in the proband of our study. LVNC or an element of other CMs may be isolated due to sharing common genetic risk [34]. These common genetic backgrounds are phenotypically expressed as overlap CMs, fulfilling the criteria for LVNC and HCM (or DCM, RCM, or ACM). The LV hypertrabeculation and HCM may present as acquired conditions due to the adaptation of the ventricular myocardium to pressure or volume overload [35]. Some LVNCs also involve the right ventricle, exhibiting high values of right ventricular noncompaction and trabeculated area [36]. Therefore, the subtypes of LVNC include benign LVNC, LVNC with arrhythmias, dilated LVNC, hypertrophic LVNC, hypertrophic dilated LVNC, restrictive LVNC, right ventricular or biventricular LVNC, and LVNC with CHD [25]. Actually, some pathogenic mutations are associated with various complex rare diseases involving more than one organ. For example, the 11-16^th exon deletion of KCNQ1 induced mild Beckwith-Wiedemann and severe LQTs [37]. Notably, in light of our literature review, LVNC with complex clinical syndromes, poor prognosis, and high mortality that may occur in the fetus or infant should be classified as another new subtype of LVNC. These syndromes may include Rubinstein–Taybi syndrome, Ehlers–Danlos syndrome, Emery–Deifuss muscular dystrophy, Danon disease, intellectual disability syndrome, Soto’s syndrome, LEOPARD syndrome, Coffin-Lowry syndrome, Cornelia de Lange syndrome, Barth syndrome, and Holt–Oram syndrome.

Two independent biological events leading to abnormal trabeculations and compaction, including hypertrabeculation and noncompaction, are demonstrated by the FKBP12-deficient mouse model for LVNC [38, 39]. Hypertrabeculation refers to the phenotype with increased number and thickness of the trabeculae at the embryonic stage. In contrast, noncompaction refers to the lack of trabecular remodeling toward the compact wall during and after trabeculations [40]. The enhanced Notch signaling induces abnormal cardiomyocyte proliferation and hypertrabeculation/noncompaction via Neuregulin1, EphrinB2, FKBP12, BMP10, TBX20 and its upstream of Sema3E/PlexinD1 signaling pathway, which potentially contributes to LVNC [41, 42]. The inhibition of Notch signaling partly normalizes the abnormal hypertrabeculation phenotype in FKBP12-deficient hearts. The planar cell polarity (PCP) signaling is also an essential molecular mechanism of polarity establishment for epithelial cells in planes orthogonal to the apical-basal axis. The noncanonical Wnt signaling, which is independent of β-catenin, is critical for PCP signaling. Together, they serve as the Wnt/PCP signaling pathway, which is composed of core components (i.e., Frizzled, Disheveled, Prickle, Vangl, and Celsr1), PCP regulator (i.e., casein kinase 1ε) and a large number of PCP effectors (i.e., Daam1, Rac1, and PhoA) [43, 44]. These molecules of Wnt/PCP signaling induced by their genetic mutations result in abnormal polarization, organization of cardiomyocyte in ventricular and outflow myocardia, and subsequent LVNC pathogenesis [40].

In this study, the proband (II: 1) carried DSC2 p.K47Rfs*2 and p.I520T variants. According to the ACMG classification criteria, the DSC2 p.K47Rfs*2 is a truncated and loss-of-function mutation, likely to cause LVNC and HCM. Compared to the MAF (< 0.01%) of inherited arrhythmia and CMs in the population, the MAF of DSC2 p.I520T (0.02%) is relatively high. Moreover, DSC2 p.I520T is not conservative in multiple species. In addition, the ECG is the main tool to judge the early changes of CMs. Especially, the abnormal changes of ECG caused by CMs are often earlier than that of the cardiac structure illustrated by echocardiography [45]. Whereas II: 3 only carrying DSC2 p.I520T and without cardiac event showed normal ECG and echocardiography. Therefore, we speculated that DSC2 p.I520T might not be pathogenic. In fact, as an important component of the cardiac desmosome, desmocollin2 maintains the normal electromechanical connection among cardiomyocytes. The desmocollin2 abnormality would lead to various CMs (such as DCM and HCM), HF, complex arrhythmia and even SCD. Recent research and our literature review showed that the abnormal components of the cardiac desmosome, including DES and DSP genes, are associated with LVNC. Desmosome is the intracellular structure that anchors intermediate filament to the plasma membrane. Desmosome, adherent junction, and gap junction are the major components of the intercalated disc, which is vital for the cell–cell adhesion and electronic coupling of cardiomyocytes [46]. Desmocollin2 and desmoglein2 (encoded by DSG2) are the important familial members of cadherin. Desmocollin2 and desmoglein2 form the adhesive heterodimer, which provides a structural framework for desmosome assembly together with armadillo proteins (plakoglobin and plakophilin, which are encoded by PG and PKP2, respectively) and the plakin family (desmoplakin, which DSP encodes) [47, 48]. The desmin filament (encoded by DES), also expressed in cardiac desmosomes, connects Z-bands, costameres, and nuclei with the cytoskeleton. The pathogenic mutations associated with desmosome proteins may cause desmosome dysfunction and remodel intercalated disc, leading to the disturbance of the mechanical–electrical coupling of cell–cell adhesion and further alteration of signaling pathways.

Previous studies show that the homozygous deletion mutation of PKP2 lead to LVNC and rapid HF, whereas the heterozygous DES p.A337P (NM_001927.3, c.1009G>C) induces LVNC and skeletal myopathy [49, 50]. A report indicates a DSC2 variant (NM_024422.3, c.1448A>T, p.N483I) in a patient with sporadic LVNC, but whether the variant is the cause of LVNC remains unclear [32]. A previous study shows that the DSC2 deletion in zebrafish induces the reduction of the desmosome plaque area, deficiency of desmosome extracellular electron-dense midlines, and disturbance of myocardial contractility [51]. Additionally, DSC2 p.Q554X (c.1660C>T) participates in the pathogenicity of familial ACM [52]. DSC2 p.A897fs*900 shows an obvious reduction in desmosome binding to plakoglobin and plakophilin [53]. The truncated mutation of DSC2 (c.2553delA) decreases the connexin 43 expression and lost plakoglobin signal [54]. Furthermore, the loss of DSC2 activates the AKT/β-catenin pathway. AKT inhibition suppresses β-catenin-dependent transcription and proliferation, which are caused by DSC2 knockdown [55]. In the present study, the 47th AA lysine of the DSC2 protein sequence at the cadherin pro is replaced by arginine, leading to premature codon termination. Consequently, DSC2 p.K47Rfs*2 remarkably and abnormally reduced the functional desmocollin2 expression, which may interfere with desmosome formation and the stability of the intermediated disc, and disturb the mechanical stress and electrical signal propagation of cardiomyocytes. Notably, the pathological and imaging changes induced by DSC2 p.K47Rfs*2 are observed in LV, resulting in the subendocardial thickening of the anterior lateral wall and interventricular septum, and thinning in part of the left ventricular wall. The ECG of the proband showed low voltage in the limb leads but no typical ST-T change, commonly suggesting diffuse myocardial lesion. The VT arises from the middle-posterior septum and lateral wall of LV. PVCs originate from the lateral wall and apex of LV and the left ventricular inflow tract, and this finding is consistent with the cardiac lesion extent. Additionally, trabeculae are observed with serious dysplasia and distributed in a rough and disordered pattern. An apparent slow blood flow is observed in the recess of trabeculae, which may increase the risk of thrombus. However, the mechanism of DSC2 p.K47Rfs*2 that induces overlap phenotypes of LVNC and HCM remains unknown. There is no research about the relationship among DSC2, Notch, and Wnt/PCP signaling pathways.

Limitation

The limitations of the present study are as follows. First, the molecular mechanism of DSC2 p.K47Rfs*2 leading to abnormalities of the desmosome structure and function should be further explored. Second, DSC2 p.K47Rfs*2 is the main cause of LVNC and HCM but still cannot rule out DSC2 p.I520T, or other variants may increase the risk of LVNC and HCM phenotype penetrance. Third, the mechanism of how the DSC2 p.K47Rfs*2 induces overlap phenotypes needs further research. Fourth, the parents and grandparents of the patient (II: 1) could not be tracked because of death. The II: 1, II: 2 and II: 3 members declined to to carry out clinical examinations and genetic testing for their offspring. Therefore, long-term follow-up is needed in the future.

Conclusion

The desmocollin2 was an important component of cardiac desmosome assembly, of which abnormality caused the dysfunction of cell–cell adhesions and intercellular gap junctions. The novel heterozygous DSC2 p.K47Rfs*2 mutation remarkably and abnormally reduced the functional desmocollin2 expression, which may consequently induce the overlap phenotypes of LVNC and HCM, complicating AF, VT, and HF. The LVNC may be one of the important phenotypes for DSC2 pathogenic mutations.

Abbreviations

CM

Cardiomyopathy

LVNC

Left ventricular noncompaction cardiomyopathy

HCM

Hypertrophic cardiomyopathy

DCM

Dilated cardiomyopathy

RCM

Restrictive cardiomyopathy

ACM

Arrhythmogenic cardiomyopathy

AF

Atrial fibrillation

VT

Ventricular tachycardia

HF

Heart failure

SCD

Sudden cardiac death

LVEF

Left ventricular ejection fraction

MYH7

Myosin heavy chain

MYBPC3

Protein-binding protein C myosin

TPM1

Tropomyosin alfa

ACTC1

Myocardial actin

TNNT2

Troponin T

DTNA

Alpha-distrobrevin

CMRI

Cardiac magnetic resonance imaging

ECGs

Electrocardiograms

NT-proBNP

The N-terminal of B-type natriuretic peptide precursor

LV

Left ventricle

Authors' contributions

Statistical analysis and manuscript drafting, Y.B.L. and J.N.H.; clinical data, family information and follow-up, Z.L.Z. and X.F.L.; designed the study and critical manuscript revision, Z.Y.H. and G.Y.X.; radiography analysis, Z.Q.Z.; echocardiogram analysis, J.Z.X.; western-blot and PCR experiments, T.F.Q, L.X.C. and J.M.H.; electrocardiogram analysis, Q.Y.W and Y.H. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [81970332], the Science and Technology Project of Zhuhai [20191210E030072], and the Medical Science and Technology Research Project of Guangdong Province [A2018043].

Availability of data and materials

The data used in this study is not publicly available, but it might be available from the corresponding author upon reasonable request and permission from relevant Chinese Authorities.

Declarations

Ethics approval

All procedures performed in studies involving human participants were following the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Medicine Ethics Committee approved the protocol of the Fifth Affiliated Hospital of Sun Yat-sen University (No. 2020K216-1).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Competing interests

The authors of this study declare that they each have no conflict of interest.